

Dear Editor,

Thank you for considering the manuscript entitled “**Roxadustat for treatment of anemia in a cancer patient with end-stage renal disease: A case report**” (73472).

We really appreciate all the valuable comments and constructive suggestions from reviewers. We have substantially revised the manuscript and a point-by-point response was enclosed. We would like to re-submit the revised manuscript to the **World Journal of Clinical Cases**, and hope it is acceptable for publication in the journal. Please do not hesitate to contact us for any question or concern.

We look forward to your final decision.

Sincerely yours

Qiao-Qiao Zhou

Responses to reviewer :

1. Reviewer #1:

Scientific Quality: Grade C (Good)

Language Quality: Grade B (Minor language polishing)

Conclusion: Minor revision

Specific Comments to Authors: The article is within the scope of the journal, and deals with an interesting topic. It's well written, and it's easy to read. The experiment is well designed and shows original and interesting results. However, to be accepted it should be improved in some aspects: a) The state of the art should be extended because it does not exist. b) It should be structured and organized in the standard sections: introduction, materials and methods, results, discussion and conclusions. c) In the discussion section, the presented work should be compared with other similar ones to establish the advances and limitations of the presented work. d) The conclusions should summarize the scientific contribution of the work and establish a set of lines of future work.

Response: We have appropriately extended the article and revised it in the abstract, core tips, treatment and other parts, especially the mechanism of roxadustat in the treatment of renal anemia in the discussion part. Currently, many studies have shown

that roxadustat can effectively treat renal anemia. The advance of this report was that roxadustat had been applied to the treatment of both renal anemia and cancer-related anemia and achieved a successful outcome. The limitation was that this was just an individual case. In the part of conclusion, we summarized that roxadustat was effective in the treatment of anemia in cancer patients with end-stage renal disease. At the same time, the combination of roxadustat and erythropoiesis-stimulating agents in the treatment of anemia could be used as a new treatment scheme. More studies are needed in the future to verify this effect and possible side effects.

2. *Science editor:*

Specific Comments To Authors: The manuscript assesses the benefits of oral roxadustat in the treatment of anemia in patients with cancer end-stage renal disease. The manuscript is well, concisely and coherently organized and presented and the style. The author is requested to add the research on the relevant mechanism of roxadustat in the treatment of anemia to the discussion. **Scientific Quality: Grade C**
Language Quality: Grade B **Recommendation: conditional acceptance**

Response: In the fifth paragraph of the discussion, we elaborated on the mechanism of roxadustat in the treatment of renal anemia.

3. *Company editor-in-chief:*

I have reviewed the Peer-Review Report, the full text of the manuscript, and the relevant ethics documents, all of which have met the basic publishing requirements of the World Journal of Clinical Cases, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office's comments and the Criteria for Manuscript Revision by Authors. Before final acceptance, uniform presentation should be used for figures showing the same or similar contents; for example, "Figure 1 Pathological changes of atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...". Please provide the original figure documents. Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor. In order to respect and protect the author's intellectual property rights and prevent others from misappropriating figures without the author's authorization or abusing figures without indicating the source, we will indicate the author's copyright for figures originally generated by the author, and if the author has used a figure published elsewhere or that is copyrighted, the author needs to be authorized by the previous publisher or the copyright holder and/or indicate the reference source and copyrights. Please check and confirm whether the figures are original (i.e. generated de novo by the author(s) for this paper). If the picture is 'original', the author needs to add the following copyright information to the bottom right-hand side of the picture in

PowerPoint (PPT): Copyright ©The Author(s) 2022. Authors are required to provide standard three-line tables, that is, only the top line, bottom line, and column line are displayed, while other table lines are hidden. The contents of each cell in the table should conform to the editing specifications, and the lines of each row or column of the table should be aligned. Do not use carriage returns or spaces to replace lines or vertical lines and do not segment cell content.

Response: We have modified the figures and tables as required.